Say hello to MassDevice +7, a bite-sized view of the top seven med-tech stories of the week. This latest feature of MassDevice.com’s coverage highlights our seven biggest and most influential stories from the week’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
If you read nothing else this weekend, make sure you’re still in the know with MassDevice +7.
Medtronic Inc. (NYSE:MDT) and Edwards Lifesciences (NYSE:EW) got the thumbs up for their heart valves from U.K. researchers, but Edwards is two years ahead of Medtronic in bringing a device to the U.S. market.
A New York State Supreme Court judge dealt a blow to Biotronik AG’s "sham recall" case against Johnson & Johnson (NYSE:JNJ) subsidiary Conor Medsystems over their defunct deal to distribute a drug-eluting stent.
Medical device industry lobby AdvaMed urges the U.S. Dept. of Health & Human Services to fully implement a health care reform provision that would require companies to report payments made to physicians and teaching hospitals.
Wall Street is still buzzing about Abbott’s (NYSE:ABT) plan to split itself into separate pharmaceutical and medical products businesses, with one investment house raising its estimate on ABT shares (which symbol the medical products business will keep) but another downgrading derivatives traded on its debt.
With high profile recalls in hip implants and defibrillators in the recent past, the FDA’s medical device review process takes another hit it doesn’t need as health care giant Johnson & Johnson weathers a storm of transvaginal mesh complaints.
Med-tech goliath Medtronic Inc. (NYSE:MDT) responded to a McAfee report on the potential for malicious hackers to use insulin pumps as a weapon for cyber assassination, detailing the steps it’s taking to confront the issue and reassure patients that the device is safe.